---
title: "Pegloticase - Gout"
sidebar: mydoc_sidebar
permalink: db09208-mesh-d006073-1.html
toc: false 
---


Path ID: `DB09208_MESH_D006073_1`
{% include image.html url="images/db09208-mesh-d006073-1.png" file="db09208-mesh-d006073-1.png" alt="db09208-mesh-d006073-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C031545 | pegloticase | Drug |
| CHEBI:27226 | uric acid | ChemicalSubstance |
| HP:0002149 | Hyperuricemia | PhenotypicFeature |
| MESH:D006073 | Gout | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Pegloticase | DECREASES ABUNDANCE OF | Uric Acid |
| Uric Acid | POSITIVELY CORRELATED WITH | Hyperuricemia |
| Hyperuricemia | MANIFESTATION OF | Gout |
|---------|-----------|---------|

Comment: This drug converts uric acid into allantoin, therefore it clears uric acid from the blood (whose elevated levels - Hyperuricemia - can lead to gout).

Reference: 
  - [https://go.drugbank.com/drugs/DB09208#mechanism-of-action](https://go.drugbank.com/drugs/DB09208#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Pegloticase#Mechanism_of_action](https://en.wikipedia.org/wiki/Pegloticase#Mechanism_of_action)
